Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
(Update) Average NHI-Market Price Gap Narrows to 5.2% to Hit Record Low
The average price discrepancy rate of listed medicines in Japan, or the gap between their NHI prices and market prices, renewed a record low at “approximately 5.2%” in 2024 on a preliminary basis, down from 6.0% the prior year, according…
To read the full story
Related Article
- Average NHI-Market Price Gap Hits Fresh Record Low at 4.8%
December 3, 2025
- NHI-Market Price Gap Likely to Narrow Further in 2025; Will It Drop into 4% Zone?
October 8, 2025
- Gist of FY2025 Drug Price Revision
December 26, 2024
- Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
December 26, 2024
- Off-Year Price Revision to Hit 53% of Listed Drugs in 2025, Down from 69%
December 23, 2024
- Three Ministers Agree on Off-Year Drug Price Revision in FY2025
December 20, 2024
- Japan Set to Settle Off-Year Debate with “x1.0” Threshold for PMP Meds/Generics, “x0.5” for LLPs
December 20, 2024
- MHLW Proposes Setting Product Scope for Off-Year Revisions by Category
December 19, 2024
- Drug Price Gap Hits Record Low, Did Distribution Guidelines Play Any Role?
December 10, 2024
- NHI-Market Price Gap Expected to Contract in 2024, Will It Enter Lower 5% Territory?
October 24, 2024
- NHI-Market Price Gap on Narrowing Trend, but Results Remain Unpredictable
September 24, 2024
- Average NHI-Market Price Gap for 2024 Revision at 6.0%, Smallest in 30 Years
December 1, 2023
REGULATORY
- Pharma Groups Press for Freeze on CEA Price Cuts, Cite Unresolved Issues
September 17, 2026
- Ueno Retained as Health Minister in Takaichi Cabinet Reshuffle
September 17, 2026
- Japan Approves Keytruda, Leqembi SC Formulations, Xcopri, and More Drugs
September 17, 2026
- Japan Finalizes Framework for OTC-Like Drug Charge Ahead of March Rollout
September 17, 2026
- Shionogi ADHD App to Go Out-of-Pocket after 2 Treatment Cycles
September 17, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…